𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression

✍ Scribed by Stephen Shibata; Warren Chow; Paul Frankel; Agnes Juhasz; Lucille Leong; Dean Lim; Kim Margolin; Robert Morgan; Edward Newman; George Somlo; Yun Yen; Timothy Synold; David Gandara; Heinz-Josef Lenz; James Doroshow

Publisher
Springer
Year
2006
Tongue
English
Weight
386 KB
Volume
59
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase I clinical trial of bortezomib in
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors
✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 114 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi

Gemcitabine plus oxaliplatin (GEMOX) com
Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma : Results of a multicenter phase 2 study
✍ Amani Asnacios; Laetitia Fartoux; Olivier Romano; Chloe Tesmoingt; Samy Louafi S πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 95 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. The authors conducted a phase 2 trial of the antiepidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in combination with the gemcitabine plus oxaliplatin (GEMOX) regimen in patients with documented progressive hepatocellular carcinoma (HCC). ## METHODS